Last Updated: July 15, 2026

Details for New Drug Application (NDA): 220711


✉ Email this page to a colleague

« Back to Dashboard


NDA 220711 describes BEQALZI, which is a drug marketed by Beone Medicines Usa and is included in one NDA. There is one patent protecting this drug. Additional details are available on the BEQALZI profile page.

The generic ingredient in BEQALZI is sonrotoclax. Additional details are available on the sonrotoclax profile page.
Summary for 220711
Tradename:BEQALZI
Applicant:Beone Medicines Usa
Ingredient:sonrotoclax
Patents:1
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 220711
Generic Entry Date for 220711*:

⤷  Start Trial

Constraining patent/regulatory exclusivity:

11,420,968

Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength1MG
Approval Date:May 13, 2026TE:RLD:Yes
Patent:11,420,968Patent Expiration:Apr 29, 2039Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:May 13, 2026TE:RLD:Yes
Patent:11,420,968Patent Expiration:Apr 29, 2039Product Flag?YSubstance Flag?YDelist Request?

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:May 13, 2026TE:RLD:Yes
Patent:11,420,968Patent Expiration:Apr 29, 2039Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links